Internship

Fall 2025 Co-Op

GMU CMC Purification Process Development

Confirmed live in the last 24 hours

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

Biotechnology
Healthcare

No H1B Sponsorship

Waltham, MA, USA

Must be able to relocate to Waltham office and work 40 hours/week for the full duration of the Co-op.

Category
Genomics
Biology & Biotech
Requirements
  • Currently pursuing a PhD, MS, or BS degree in biological sciences, genetic engineering/ engineering sciences with relevant study experience.
  • Must be enrolled in school the semester following your co-op with Sanofi.
  • Must be able to relocate to our Waltham office location and work 40hrs/week for the full duration of the Co-op.
  • Must have permanent US work authorization.
  • Understanding of cell engineering, molecular biology, virology and immunology concepts.
  • Knowledge and understanding of technologies and operations such as: Chromatography, tangential flow filtration, normal flow filtration, and/or viral clearance and inactivation; Advanced analytical tools to characterize protein and viral vectors.
  • Work under minimal supervision and function within a collaborative, team-oriented environment.
  • Ability to work in Biosafety Level 2, follow safe lab procedures, and maintain good laboratory practices (GLPs) including detail-oriented laboratory notebook documentation.
Responsibilities
  • Design, execute, and analyze viral vector purification experiments.
  • Perform analytical characterization of samples and analyze results.
  • Work with cross-functional team for feedback and present findings.
  • Contribute to technical reports and/or external publications if appropriate to project topic and level of experience.

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi differentiates itself from competitors by its strong commitment to scientific innovation and a diverse product portfolio that includes prescription medicines and vaccines. Its goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Stage

IPO

Total Funding

$2B

Headquarters

Paris, France

Founded

1973

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's digital health initiatives improve patient engagement and medication adherence.
  • Tolebrutinib offers a competitive edge in the MS market with its unique BTK inhibitor.
  • Dupixent's EU approval for young children expands its market and addresses unmet needs.

What critics are saying

  • Tolebrutinib faces potential safety concerns due to liver enzyme elevations in trials.
  • Digital health solutions like 'MyWay' may encounter patient adoption and data privacy issues.
  • Sanofi's reliance on partnerships exposes it to risks from partners' financial difficulties.

What makes Sanofi unique

  • Sanofi's partnership with BrightInsight enhances digital health solutions for specialty therapies.
  • Tolebrutinib's FDA Breakthrough Therapy designation sets it apart in the MS treatment landscape.
  • Sanofi's AI collaboration with Formation Bio and OpenAI accelerates patient recruitment in trials.

Help us improve and share your feedback! Did you find this helpful?